Category Archives: IP

Weak IP Protection Threatens Asia-Pac Biotech Boom

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital  investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013,  whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]
Also posted in Deals, Emerging Markets, Global | Tagged , , , | Leave a comment

Innovation on the Rise in India

India has a name when it comes to generic drug development. According to a recent research on patent applications carried out by Withers & Rogers, innovation by Indian pharmaceutical companies has increased over the past few years; however, the quality did not match the standard seen in Europe. The research was conducted using a software […]
Also posted in Global, R&D | Tagged , , | Leave a comment

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Also posted in Biotech, FDA, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , | Leave a comment

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Also posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Also posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta